Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xenetic Biosciences (XBIO) Shares Outstanding (Weighted Average) (2023 - 2025)

Xenetic Biosciences' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 10.4% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, up 10.4%, while the annual FY2025 figure was $1.7 million, 10.4% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $1.7 million in Q4 2025 per XBIO's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.7 million in Q4 2025 to a low of $800.0 in Q1 2025.
  • Average Shares Outstanding (Weighted Average) over 3 years is $822230.0, with a median of $991836.5 recorded in 2023.
  • The largest YoY upside for Shares Outstanding (Weighted Average) was 73297.1% in 2024 against a maximum downside of 73.75% in 2024.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $2100.0 in 2023, then soared by 73297.1% to $1.5 million in 2024, then increased by 10.4% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for XBIO's Shares Outstanding (Weighted Average) are $1.7 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025).